Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 14:57:26 GMT 2023
by
admin
on
Sat Dec 16 14:57:26 GMT 2023
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
2PDN1S3FVX
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2PDN1S3FVX
Created by
admin on Sat Dec 16 14:57:30 GMT 2023 , Edited by admin on Sat Dec 16 14:57:30 GMT 2023
|
PRIMARY | |||
|
Q07869
Created by
admin on Sat Dec 16 14:57:30 GMT 2023 , Edited by admin on Sat Dec 16 14:57:30 GMT 2023
|
PRIMARY |
Linkage Type | Residue Index | |||
---|---|---|---|---|
COORDINATION COMPOUND | 1_139 | 1_143 | 1_153 | 1_156 |
COORDINATION COMPOUND | 1_102 | 1_105 | 1_119 | 1_122 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVATOR -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
ACTIVATOR -> TARGET | |||
|
ACTIVATOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Ki=7.1 micromolar (Supplementary Fig. S5; http://clincancerres.aacrjournals.org/content/22/10/2508.figures-only)
IN-VITRO
IC50
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
WEAK AGONIST->TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
WEAK AGONIST->TARGET |
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
SELECTIVE
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Tesaglitazar is a novel dual-acting peroxisome proliferator-activated receptor alpha and gamma agonist.
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
ACTIVATOR -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
INHIBITOR
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
ACTIVATOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
AGONIST
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
The PPARα potency and selectivity of 3 were further confirmed by testing it in cotransfection assays in HepG2 cells using full length human PPARα and PPARγ receptors..
EC50
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT | CHEMICAL |
|